title: Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.
authors.affiliation: Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia (D.J.R); and Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (J.J.P.K.).
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Rader
authors.forename: John J P
authors.initials: JJ
authors.lastname: Kastelein
mesh_terms: D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001055:Apolipoproteins B / Q000037:antagonists & inhibitors; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D002352:Carrier Proteins / Q000037:antagonists & inhibitors; D008078:Cholesterol, LDL / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D006720:Homozygote; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy* / Q000235:genetics*; D009841:Oligonucleotides / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000924:Anticholesteremic Agents; D001055:Apolipoproteins B; C473731:BMS201038; D001562:Benzimidazoles; D002352:Carrier Proteins; D008078:Cholesterol, LDL; D009841:Oligonucleotides; C106092:microsomal triglyceride transfer protein; C524142:mipomersen
keywords: anticholesteremic agents; cholesterol; hyperlipoproteinemia type 2; lipoproteins, LDL